Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled date : 2021 - 12 - 09 save search
SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient
Published: 2021-12-09 (Crawled : 20:00) - biospace.com/
SQZ | $0.435 0.0% 30M
|
Health Technology
|
| O: -1.88%
H: 4.08%
C: 1.22%
hpv therapy biotech iot
Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
AVCO | $0.45 -16.15% 31.11%
|
Health Technology
|
| O: -3.14%
H: 3.24%
C: -1.2%
technology therapy designation
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.03%
H: 2.75%
C: -2.6%
sp-102 trial therapeutics potential opioid positive therapy results phase 3 topline
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
Published: 2021-12-09 (Crawled : 14:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: -2.59%
H: 1.04%
C: -5.89%
ata2271 solid tumors therapeutics therapy results iot t-cell
Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for Aficamten
Published: 2021-12-09 (Crawled : 13:00) - globenewswire.com
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -2.93%
H: 0.0%
C: 0.0%
fda therapy breakthrough therapy designation
Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for AficamtenFDA Granted Designation for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy Based on Results of REDWOOD-HCM
Published: 2021-12-09 (Crawled : 13:00) - biospace.com/
CYTK | $67.49 0.73% 0.73% 1.5M
|
Health Technology
|
| O: -2.93%
H: 0.0%
C: 0.0%
treatment fda cardio granted therapy results breakthrough therapy designation
Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit
Published: 2021-12-09 (Crawled : 12:30) - prnewswire.com
CGEN | $2.03 3.57% 3.45% 450K
|
Health Technology
|
| O: 6.91%
H: 2.16%
C: 0.86%
com701 therapy
uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
Published: 2021-12-09 (Crawled : 12:30) - globenewswire.com
QURE | $4.68 -0.64% -0.64% 550K
|
Health Technology
|
| O: 5.19%
H: 1.33%
C: -6.6%
gene therapy trial therapy
Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
Published: 2021-12-09 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 7.46%
H: 0.31%
C: -12.81%
ocu400 new drug fda application gene therapy drug trial fda acceptance phase 1 therapy retina
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.